Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Am J Clin Oncol. 2016 Dec;39(6):614–618. doi: 10.1097/COC.0000000000000108

Table 1. Studies Included in Pooled Analysis.

References Phase Patients (n) Chemotherapy Median (mo) TTP/PFS Median OS (mo)
Ko et al19 II 52 FDR gemcitabine (1000 mg/m2) day 1 + cisplatin (20 mg/m2) day 1 + bevacizumab (10 mg/kg) day 1; every 2 wk 6.6 (TTP) 8.2
Javle et al20 II 50 Gemcitabine (1000 mg/m2) day 1-8 + capecitabine (1300 mg/m2) day 1-14 + bevacizumab (15 mg/kg) day 1; every 3 wk 5.8 (PFS) 4.8
Fogelman et al17 II 50 FDR gemcitabine (1000 mg/m2) day 1 + oxaliplatin (100 mg/m2) day 2 + bevacizumab (10 mg/kg) day 1; every 2 wk 4.9 (PFS) 11.9
Martin et al16 II 42 FDR gemcitabine (1000 mg/m2) day 1 + infusional 5-fluorouracil (2400 mg/m2) day 1 + bevacizumab (10 mg/kg) day 1; every 2 wk 5.9 (PFS) 7.4

FDR indicates fixed dose rate; OS, overall survival; PFS, progression free survival; TTP, time to progression.